1. |
Pakos EE, Stafilas KS, Tsekeris PG, et al. Combined radiotherapy and indomethacin for the prevention of heterotopic ossification after total hip arthroplasty. Strahlenther Onkol, 2009, 185(8):500-505.
|
2. |
Le Duff MJ, Takamura KB, Amstutz HC. Incidence of heterotopic ossification and effects of various prophylactic methods after hip resurfacing. Bull NYU Hosp Jt Dis, 2011, 69(Suppl 1):S36-S41.
|
3. |
Xu JC, Wu T, Wu GH, et al. Leptin expression by heterotopic ossification-isolated tissue in rats with Achilles' tenotomy. Saudi Med J, 2009, 30(5):605-610.
|
4. |
徐俊昌, 吴涛, 吴桂华, 等. 跟腱切断法诱导大鼠异位骨化动物模型的建立. 中国矫形外科杂志, 2009, 17(8):625-627.
|
5. |
Zhang K, Wang L, Zhang S, et al. Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy. Eur J Orthop Surg Traumatol, 2013, 23(2):145-148.
|
6. |
Ma Y, Ma L, Guo Q, et al. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res, 2010, 29:85.
|
7. |
Zhu H, Zhou X, Redfield S, et al. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res, 2013, 5(3):368-378.
|
8. |
Lin L, Shen Q, Xue T, et al. Heterotopic ossification induced by Achilles tenotomy via endochondral bone formation:expression of bone and cartilage related genes. Bone, 2010, 46(2):425-431.
|
9. |
FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med, 2001, 345(6):433-442.
|
10. |
Jouzeau JY, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflamatory drugs. Drugs, 1997, 53(4):563-582.
|
11. |
Wittenberg RH, Peschke U, Bötel U. Heterotopic ossification after spinal cord injury. Epidemiology and risk factor. J Bone Joint Surg (Br), 1992, 74(2):215-218.
|
12. |
毛玉江, 王满宜, 吕厚山. 吲哚美辛干预家兔髋关节异位成骨的实验观察. 中华创伤骨科杂志, 2005, 7(5):447-451.
|
13. |
Murat N, Hocaoglu N, Karatosun V, et al. The effects of non-selective and cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs on heterotopic ossification in rats. Med Sci Monit, 2005, 11(12):BR449-451.
|
14. |
Rapuano BE, Boursiquot R, Tomin E, et al. The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model. Arch Orthop Trauma Surg, 2008, 128(3):333-344.
|
15. |
Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone:bad cop, good cop? Trends Endocrinol Metab, 2010, 21(5):294-301.
|
16. |
Toom A, Arend A, Gunnarsson D, et al. Bone formation zones in heterotopic ossifications:histologic findings and increased expression of bone morphogenetic protein 2 and transforming growth factors beta2 and beta3. Calcif Tissue Int, 2007, 80(4):259-267.
|
17. |
Macfarlane RJ, Ng BH, Gamie Z, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother, 2008, 9(5):767-786.
|
18. |
Günal I, Hazer B, Seber S, et al. Prevention of heterotopic ossification after total hip replacement:a prospective comparison of indomethacin and salmon calcitonin in 60 patients. Acta Orthop Scand, 2001, 72(5):467-469.
|
19. |
Knelles D, Barthel T, Karrer A, et al. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg (Br), 1997, 79(4):596-602.
|
20. |
Barbato M, D'Angelo E, Di Loreto G, et al. Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty:results from an Italian multicenter, prospective, observational survey. J Orthop Traumatol, 2012, 13(2):63-67.
|